Ocular hypertension following intravitreal antivascular endothelial growth factor therapy: Review of the literature and possible role of nitric oxide

Journal of Glaucoma

Volumn 25, Issue 3, 2016, Pages 291-300

  Morshedi, R Grant ^a   Ricca, Aaron M ^a   Wirostko, Barbara M ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti VEGF; Glaucoma; Intraocular pressure; Intravitreal; Nitric oxide; Ocular hypertension

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; APTAMER; HYBRID PROTEIN; NITRIC OXIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ARTICLE; DATA BASE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL RECORD REVIEW; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TRABECULAR MESHWORK; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; OCULOPLETHYSMOGRAPHY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; APTAMERS, NUCLEOTIDE; BEVACIZUMAB; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; NITRIC OXIDE; OCULAR HYPERTENSION; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916898769     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0000000000000173     Document Type: Article

References (61)

1. Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930-934, e931.
2. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18:658-661.
3. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol [Journal canadien d'ophtalmologie]. 2007;42:807-811.
4. Theoulakis PE, Lepidas J, Petropoulos IK, et al. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010; 227:280-284.
5. Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119:321-326.
6. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013;33:179-187.
7. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111-1114.
8. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocular Pharmaco Ther. 2010;26:105-110.
9. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250:1435-1440.
10. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-1665.
11. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31: 1028-1035.
12. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010;4:28-29.
13. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30: 887-892.
14. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3 pt 2):H1054-H1058.
15. Buys ES, Ko YC, Alt C, et al. Soluble guanylate cyclase alpha1-deficient mice: a novel murine model for primary open angle glaucoma. PloS One. 2013;8:e60156.
16. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol. 2008;294:C1378-C1386.
17. Ellis DZ, Dismuke WM, Chokshi BM. Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. Investig Ophthalmol Vis Sci. 2009;50:1808-1813.
18. Ellis DZ, Sharif NA, Dismuke WM. Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling. Investig Ophthalmol Vis Sci. 2010;51:5817-5824.
19. Meyer P, Champion C, Schlotzer-Schrehardt U, et al. Localization of nitric oxide synthase isoforms in porcine ocular tissues. Cur Eye Res. 1999;18:375-380.
20. Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Investig Ophthalmol Vis Sci. 1995;36:1774-1784.
21. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Investig Ophthalmol Vis Sci. 1995;36:1765-1773.
22. Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Investig Ophthalmol Vis Sci. 1994;35:2515-2520.
23. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50:203-218.
24. Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett. 2011;21:3216-3221.
25. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011;93:250-255.
26. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Archiv Ophthalmol. 2010;128:1523-1527.
27. Hohn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol. 2010;248:1371-1375.
28. Sharei V, Hohn F, Kohler T, et al. Course of intraocular pressure after intravitreal injection of 0.05mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20:174-179.
29. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009; 23:181-185.
30. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007;27:1044-1047.
31. Frenkel RE, Mani L, Toler AR, et al. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143:1034-1035.
32. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol. 2006;141:200-201.
33. Kim GN, Han YS, Chung IY, et al. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension. Semin Ophthalmol. 2013;28:61-67.
34. Menke MN, Salam A, Framme C, et al. Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab. Ophthalmologica. 2013;229:168-172.
35. Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2013;44:460-464.
36. Segal O, Ferencz JR, Cohen P, et al. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Isr Med Assoc J. 2013;15:352-355.
37. Sobac? G, Güngör R, Ozge G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol. 2013;6:211-215.
38. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Investig Ophthalmol Vis Sci. 2012;53:6214-6218.
39. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21:241-247.
40. Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32:1295-1301.
41. Horsley MB, Mandava N, Maycotte MA, et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150 :558-561, e551.
42. Lee K, Yang H, Lim H, et al. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina. 2009;29:1409-1417.
43. Seth RK, Salim S, Shields MB, et al. Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. Retina. 2009;29:956-959.
44. El Chehab H, Le Corre A, Giraud JM, et al. Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections. J Fr Ophtalmol. 2012;35:614-621.
45. Kotliar K, Maier M, Bauer S, et al. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85:777-781.
46. Gregori NZ, Weiss MJ, Goldhardt R, et al. Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injection. J Glaucoma. 2013, Apr 29, 2013. [Epub ahead of print].
47. Katayama BY, Bonini-Filho MA, Messias AM, et al. Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma. 2014;23:461-463.
48. Knip MM, Valimaki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol. 2012;90:254-258.
49. Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology. 2014;121:1102-1108.
50. Loukianou E, Brouzas D, Apostolopoulos M. Sustained ocular hypertension following intravitreal injections of 0.5mg/0.05mL ranibizumab. Int Ophthalmol. 2011;31:211-213.
51. Bakri SJ, McCannel CA, Edwards AO, et al. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:955-958.
52. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40:293-295.
53. Skalicky SE, Ho I, Agar A, et al. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging. 2012;43:328-334.
54. Kernt M, Welge-Lussen U, Yu A, et al. Bevacizumab is not toxic to human anterior-And posterior-segment cultured cells. Ophthalmologe. 2007;104:965-971.
55. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19:437-441.
56. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795.
57. Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56:1131-1136.
58. Dai F, Shu L, Bian Y, et al. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and metaanalysis of all randomized clinical trials. Clin Drug Investig. 2013;33:779-788.
59. Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 2013;16:289-295.
60. Stumpff F, Wiederholt M. Regulation of trabecular meshwork contractility. Ophthalmologica. 2000;214:33-53.
61. Bausch+Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed from Nicox. 2013. Available at: http://www.bausch.com/our-company/recent-news/2013-Archive/bausch-lomb-phase-3-program-for-glaucoma-drugcandidate-nicox/. Accessed January 12, 2013.